
    
      This study is designed to assess the efficacy and safety of TOP1630 ophthalmic solution in
      subjects with Dry Eye Syndrome (DES).

      Eligible subjects will be randomized double masked to either TOP1630 or placebo for a
      duration of 28 days' treatment.
    
  